Arixtra® (fondaparinux sodium): shortage following interrupted production due to a minor defect affecting the needle guard
2017.07.18
Active substance: fondaparinux sodium
The company Aspen Pharma Trading Limited is circulating information on the fact that a minor defect affecting the needle guard of some Arixtra syringes has led to quarantine of several batches and interrupted production.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN